The team then selected a subset of data for developing a panel for differentiating between pancreatic
cancer and healthy pancreas tissue and thereafter applied this «Pancreatic Cancer Predictor» to the remaining datasets for independent validation to confirm the accuracy of the ma
cancer and healthy
pancreas tissue and thereafter applied this «Pancreatic
Cancer Predictor» to the remaining datasets for independent validation to confirm the accuracy of the ma
Cancer Predictor» to the
remaining datasets for independent validation to confirm the accuracy of the markers.
With survival rates that haven't changed significantly for decades,
cancers of the brain, lung, oesophagus and
pancreas are notoriously difficult to treat and
remain diseases of substantial unmet need.